ClinicalTrials.gg
Active, not recruitingNCT03828201DRAMATICUpdated Jul 8, 2026

Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB

A Phase 2 interventional study of Delamanid and Levofloxacin in Tuberculosis, Multidrug-Resistant, sponsored by Boston University. Active, not recruiting at 2 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Boston University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
271
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing OPC-67683 in Tuberculosis, Multidrug-Resistant — none open to participants now, 3 under way, 2 of them phase 3. OPC-67683 · Tuberculosis, Multidrug-Resistant.

Enrollment
7th of 14
271 · median 243
Started
2022
the only one that year
Phase 2
6 of 14
none open now
Registered
11th of 14
by date
Lead sponsor
2 of 14
Boston University

Among the 14 studies testing OPC-67683 in Tuberculosis, Multidrug-Resistant, this one is the 7th largest by enrollment, is the only one that started in 2022, is one of 6 in phase 2, and was the 11th registered.

Tuberculosis, Multidrug-Resistant

132 studies on the registry are indexed under Tuberculosis, Multidrug-Resistant; 25 are open to participants now.

Browse Tuberculosis, Multidrug-Resistant studies →

Open to participants now

None of the 14 studies testing OPC-67683 in Tuberculosis, Multidrug-Resistant is open now. The open studies under Tuberculosis, Multidrug-Resistant, anywhere →

About OPC-67683

OPC-67683: first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing OPC-67683 in Tuberculosis, Multidrug-Resistant as a file.
02

Study summary

Multidrug-resistant tuberculosis (MDR-TB) is tuberculosis (TB) that is resistant to at least isoniazid and rifampicin, the two most important anti-TB drugs. It occurs in 3.6% of newly diagnosed TB patients in the world and 17% of patients who have been previously treated. In 2017, approximately 600,000 people were estimated to have acquired MDR-TB. However, only 25% of persons with MDR-TB were diagnosed and started on treatment, reflecting inadequate diagnostic capacity and lack of TB treatment capacity.

In this multicenter, randomized, partially blinded, four-arm, phase 2 study, the investigators will examine the efficacy and safety of an all-oral regimen of bedaquiline, delamanid, levofloxacin, linezolid, and clofazimine given for 16, 24, 32 or 40 weeks

Read the detailed description

Multidrug-resistant tuberculosis (MDR-TB) is tuberculosis that is resistant to at least isoniazid and rifampicin, the two most important drugs in treating TB. In 2017, approximately 558,000 new people were estimated to have developed MDR-TB, and 8.5% of the cases had extensively drug-resistant tuberculosis (XDR-TB).(1) Current WHO-endorsed MDR-TB treatment regimens take 9-20 months to complete and are associated with substantial toxicity, including deafness from injectable agents, hepatitis from pyrazinamide and severe neuropathy from linezolid. Given the long duration and toxicities of MDR-TB regimens, it is perhaps not surprising that WHO reports that only 25% of patients with MDR-TB are enrolled into WHO-endorsed treatment regimens. Thus, there is an urgent need for shorter, less toxic treatments for MDR-TB. This proposal will determine the efficacy, safety, tolerability and optimal duration of a novel, all oral MDR-TB treatment regimen while addressing three major challenges with innovations that have the potential to transform future trials.

The proposed DRAMATIC (Duration Randomized Anti-MDR-TB And Tailored Intervention Clinical) Trial is a multicenter, randomized, partially blinded, four-arm, phase 2 trial that will examine an injectable- and pyrazinamide-sparing regimen of bedaquiline, delamanid, levofloxacin, linezolid, and clofazimine. The DRAMATIC regimen limits the administration of linezolid to the initial 8 weeks of treatment, the window before linezolid-related neuropathy occurs. Animal and human studies provide evidence for the potential efficacy of this 5-drug regimen, but the optimal duration of treatment remains uncertain.(2-4)

Primary Objectives:

  1. Describe the relationship between the duration of the experimental regimen and the proportion of participants with sustained cure at 76 weeks after randomization without treatment failure or relapse.
  2. Describe the relationship between baseline prognostic risk strata and sustained cure at 76 weeks after randomization without treatment failure or relapse.
  3. Evaluate the association between novel biologic markers and sustained cure at 76 weeks after randomization without treatment failure or relapse.

    Secondary Objectives:

  4. Identify the shortest duration of the study regimen that has acceptable safety and efficacy for a Phase 3 clinical trial of the DRAMATIC regimen for treatment of MDR-TB.
  5. Describe the frequency, magnitude, time course of and risk factors for QTc prolongation associated with the study regimen.
  6. Demonstrate the feasibility and efficiency of implementing the new duration-randomized design in a multi-centre randomized trial of drug-resistant TB.
  7. Determine if time to sputum culture conversion predicts optimal duration of treatment when stratified by extent of disease.
  8. Describe the relationship between the duration of the experimental regimen and the proportion of participants with sustained cure at 90 weeks and up to 104 weeks after randomization without treatment failure or relapse.
  9. Assess vital status at 90 weeks and up to 132 weeks post randomization.

Development of a shorter, better-tolerated treatment regimen will greatly enhance the ability of TB control programs to treat the growing number of patients. The DRAMATIC Trial will employ an innovative and efficient new design to establish a robust, nontoxic MDR-TB treatment regimen and identify the minimal duration for which it needs to be administered. These results will speed the process of moving forward to a confirmatory phase 3 clinical trial and increase the likelihood that such a trial is successful.

03

Conditions studied

  • Tuberculosis, Multidrug-Resistant

Keywords

  • bedaquiline (BDQ)
  • delamanid (DLM)
  • linezolid (LZD)
  • levofloxacin (LFX)
  • clofazimine (CF)
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females age ≥12 years. Prior to study procedures, if ≥18 years of age, provides ; if \<18 years of age, child provides informed assent and has a parent or guardian who provides informed consent on the participant's behalf.
  2. Has pulmonary TB based on investigator assessment of all available information (e.g., chest radiograph, sputum smear, culture, molecular testing).
  3. Has a sputum sample that is positive for M. tuberculosis that is rifamycin-resistant and fluoroquinolone-susceptible by molecular assay.
  4. Is seropositive or seronegative; HIV serostatus must be assessed at screening if either (a) HIV serostatus is unknown, or (b) the last documented negative HIV test was more than two (2) months prior to screening.
  5. Willing to attend scheduled follow-up visits and undergo study assessments.
  6. Participants of must agree either (a) to practice an adequate (defined as one of the following oral contraceptives, intrauterine devices, contraceptive implants under the skin, contraceptive rings or patches or injections, diaphragms with spermicide or condoms with foam) or (b) to abstain from heterosexual intercourse during study regimen.

Exclusion criteria

Exclusion Criteria:

  1. Current MTB isolate is known at screening to be fluoroquinolone-resistant.
  2. History of allergy () or intolerability to one or more agents in the study regimen (i.e., Delamanid, Linezolid, Levofloxacin, Clofazimine or Bedaquiline)
  3. History of serotonin syndrome
  4. History of symptomatic ventricular arrhythmia or is taking anti-arrhythmic agents
  5. History of optic neuropathy or peripheral neuropathy
  6. History of Ehlers-Danlos Syndrome, Marfan Syndrome or aortic aneurism
  7. History of prior treatment with delamanid or linezolid for TB for greater than one month.
  8. Has at screening received ≥14 days of anti-TB drugs during current TB episode
  9. Has at screening a score of ≤40 or, in the opinion of the Investigator, is unlikely to survive 76 weeks.
  10. Has at screening laboratory results that meet one or more of the following criteria:

    • concentration 8.0 g/dL (\<80 g/L)
    • count of \<80,000/mm3
    • (ANC) \<2000/ mm3
    • Serum creatinine >2.0 mg/dL (>177 µmol/L)
    • Serum >3x (ULN)
    • Total >3x upper limit of normal (ULN)
    • Serum albumin \<2.8 g/dL (\<28 g/L)
    • For women of , a positive or indeterminate serum pregnancy test
  11. For women of childbearing potential, has a positive or indeterminate urine pregnancy test on the day of randomization.
  12. Has at screening a mean >450 msec based on three ECGs.
  13. At screening requires ongoing use of prohibited drugs indicated in section 4.2
  14. At screening, has weight less than 33 Kg
  15. In the investigator's judgement is unable to provide consent (if ≥18 years of age) or unable to provide assent (if >12 years of age).
  16. History of congestive heart failure
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
271 participants (actual)

Study arms

  • Experimental
    Investigational: DRAMATIC-16 weeks

    delamanid 300 mg orally, by mouth (PO) once a day (QD), 16 weeks levofloxacin 1000 mg PO QD, 16 weeks clofazimine 100 mg PO QD, 16 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only

    Drug: Delamanid · Drug: Levofloxacin · Drug: Bedaquiline · Drug: Clofazimine · Drug: Linezolid

  • Experimental
    Investigational: DRAMATIC-24 weeks

    delamanid 300 mg orally, by mouth (PO) once a day (QD), 24 weeks levofloxacin 1000 mg PO QD, 24 weeks clofazimine 100 mg PO QD, 24 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only

    Drug: Delamanid · Drug: Levofloxacin · Drug: Bedaquiline · Drug: Clofazimine · Drug: Linezolid

  • Experimental
    Investigational: DRAMATIC-32 weeks

    delamanid 300 mg orally, by mouth (PO) once a day (QD), 32 weeks levofloxacin 1000 mg PO QD, 32 weeks clofazimine 100 mg PO QD, 32 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only

    Drug: Delamanid · Drug: Levofloxacin · Drug: Bedaquiline · Drug: Clofazimine · Drug: Linezolid

  • Experimental
    Investigational: DRAMATIC-40 weeks

    delamanid 300 mg orally, by mouth (PO) once a day (QD), 40 weeks levofloxacin 1000 mg PO QD, 40 weeks clofazimine 100 mg PO QD, 40 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only

    Drug: Delamanid · Drug: Levofloxacin · Drug: Bedaquiline · Drug: Clofazimine · Drug: Linezolid

Interventions

  • DrugOPC-67683Studies of OPC-67683OPC-67683 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Frequency: daily Route of administration: oral Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.

    Also known as: Deltyba

  • Frequency: daily Route of administration: oral Levofloxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis.

    Also known as: Levaquin

  • Frequency: daily Route of administration: oral Bedaquiline is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

    Also known as: Sirturo

  • Frequency: daily Route of administration: oral Clofazimine has shown activity against multidrug-resistant tuberculosis (MDR-TB) and is now recommended by the World Health Organization (WHO) to treat drug resistant tuberculosis as a "Group B" drug. It is thought that clofazimine acts by inhibiting the formation of matrixes within the DNA and thus delaying the growth of the bacterium. Clofazimine first received FDA approval in 1986, although its use in the treatment of MDR-TB has not been approved by any stringent regulatory authorities and it is therefore used "off-label" for this function.

    Also known as: Lamprene

  • Frequency: daily Route of administration: oral Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics.

    Also known as: Zyvox

06

What researchers measure

Primary outcomes

  1. Treatment Efficacy - Frequency of "successful treatment" outcomes

    A participant's outcome will be classified as successful if, at 76 weeks after initiation of treatment, they have a "negative" sputum culture and were not previously classified as unsuccessful; if the participant is unable to produce sputum at that time, the outcome will be classified as successful if they had a negative culture result at the last visit at which they had a sputum culture result. A participant's outcome will be classified as unsuccessful if any of the following occur prior to week 76: Addition or replacement of 2 or more anti-tuberculosis (TB) drugs from the assigned regimen, the participant has a positive culture for M. tuberculosis and that isolate is not demonstrated to be genetically different from the initial isolate, undergoing surgery for multidrug-resistant TB (MDR-TB), lost to follow-up, surgery for MDR-TB, extended treatment, and death.

    Time frame: Week 76

  2. Treatment Safety - Frequency of participants with grade 3, 4, or 5 adverse events

    The primary outcome for safety are Grade 3, 4, or 5 adverse events

    Time frame: 44 weeks

Secondary outcomes

  1. Efficacy outcome- Frequency of participants who survive

    Evaluate survival at 90 weeks and up to 132 weeks post randomization.

    Time frame: Week 90 and up to Week 132

07

Study locations

2 sites
08

References and documents

Publications

  • Kaur P, Chaisson LH, Kiragu ZW, Buddadhumaruk P, Austin AF, Gao Y, Wirtz VJ, Arbeit RD, Fetalvero KB, Nguyen HB, Nguyen NV, Ha H, Eisenach K, Walter ND, Mitnick CD, Gler MTS, Phan H, Nahid P, Phillips PPJ, Horsburgh CR, Velasquez GE. Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial. Contemp Clin Trials. 2025 May;152:107875. doi: 10.1016/j.cct.2025.107875. Epub 2025 Mar 8. PubMed 40064371 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for May 2027, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2019
First posted
Feb 4, 2019
StartActual
Jun 7, 2022
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03828201
Lead sponsor
Boston University
Collaborators
Novartis Pharmaceuticals, Pfizer, Otsuka Pharmaceutical Co., Ltd., University of California, San Francisco, National Institute of Allergy and Infectious Diseases (NIAID), University of Colorado, Denver, Harvard Medical School (HMS and HSDM), National Lung Hospital, Vietnam, TB-HIV Innovations & Clinical Research Foundation Corp, Philippines
Responsible party
Charles R Horsburgh (Professor of Epidemiology, Boston University, Boston University) — Principal investigator
First posted
Feb 4, 2019
Start date
Jun 7, 2022
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Charles Horsburgh, MD
principal investigator · Boston University
Payam Nahid, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: OPC-67683 · Levofloxacin · Bedaquiline · Clofazimine · Linezolid

Start the discussion